References
- UNAIDSReport on the Global AIDS epidemicNew YorkUNAIDS2002
- World Health OrganizationScaling up antiretroviral therapy in resource-limited settings Guidelines for a public health approachGeneva, SwitzerlandWorld Health Organization2003
- FoisyMMGoughKQuanCMHarrisKIbanezDPhillipsAHospitalization due to adverse drug reactions and drug interactions before and after HAARTCan J Infect Dis20001119320118159290
- MontessoriVPressNHarrisMAkagiLMontanerJSAdverse effects of antiretroviral therapy for HIV infectionCMAJ2004170667672
- WesterCWOkezieOAThomasAMBussmannHHigher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trialAIDS200746318322
- Holkmann OlsenCMocroftAKirkOInterruption of combination antiretroviral therapy and risk of clinical diseases progression to AIDS or deathHIV Med200789610417352766
- Rodriguez-ArenasMAJarrinIdel AmoJDelay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injection drug users in SpainAIDS Res Hum Retroviruses20062271572316910826
- RattanAKumarAAntibiotics – use and misuseJ Acad Hosp Adm19957192210154802
- StensonBSyhakhangLErickssonBTomsonGReal world pharmacy: assessing the quality of private pharmacy practice in Lao People’s Democratic RepublicSoc Sci Med20015239340411330774
- GoodmanCKachurSPAbdullaSBlolandPMillsADrug shop regulation and malaria treatment in Tanzania – why do shops break the rules, and does it matter?Health Policy Plan20072239340317921151
- GoelPRoss-DegnanDBermanPSoumeraiSRetail pharmacies in developing countries: a behavior and intervention frameworkSoc Sci Med199642115511618737433
- RawlingsMKSmithKYRecognizing and managing common toxicities in patients receiving antiretroviral therapyAIDS2004141215
- WoodEMontanerJSYipBTyndallMWAdherence and plasma HIV RNA responses to HAART among HIV-1 infected injection drug usersCMAJ200316965666114517122
- MinziONgaimisiEBioanalytical method for determination of nevirapine in-vivo in resource constrained laboratoriesJ Chem Pharm Res20102431439
- RendónANúñezMJiménez-NácherIGonzález de RequenaDGonzález-LahozJSorianoVClinical benefit of interventions driven by therapeutic drug monitoringHIV Med2005636036516156885
- de MaatMMHuitemaADMulderJWSubtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV careTher Drug Monit20032536737312766566
- WitFWKesselringAMGrasLDiscontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort studyClin Infect Dis20084693394018271750
- BattegayMNueschRHirschelBKaufmannGRImmunological recovery and antiretroviral therapy in HIV-1 infectionLancet Infect Dis2006628028716631548
- KnobelHGuelarAMonteroMCarmonaALuqueSGonzálezARisk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell countHIV Med20089141818199168